Lancet oncol: Papiss is given the efficacy and safety of boronitzomi to treat recurring/refracilable multiple myeloma

Treatment options for patients with recurring/recurring multiple myeloma need to be improved.
less toxic effects of subdermose injection of boron tazome, which has now replaced intravenous drugation (boron tezometha).
PANORAMA 3 trial was designed to assess the activity and safety of three different dose options for oral pabinostat combined with boroniczomi (subskin) and dexamethason (oral) for use in such patients.
the trial, an open-label, randomized Phase 2 trial conducted by 71 medical institutions in 21 countries, recruited patients over the age of 18 with recurring/resuscable multiple myeloma and required the subjects to have received 1-4 lines of treatment in the past.
the patient was divided into three groups at 1:1:1, and the doses of Parbis were the same as 20mg 3 times/week (group A), 20mg 2 times/week (group B) or 10mg 3 times/week (group C), boronicazome and dexamisson, respectively.
end of the treatment was the overall remission rate after 8 sessions (21 days/course).
April 27, 2016 - January 17, 2019, a total of 248 patients were randomly grouped (82 in Group A, 83 in Group B, and 83 in Group C).
14.7 months (IQR 7.8-24.1) of the total follow-up time.
after each of the eight courses were: Group A 62.2%, Group B 65.1% and Group C 50.6%.
the rates of adverse reactions at levels 3-4 in groups A, B and C were 91%, 83% and 75%, respectively, and the most common adverse reactions at levels 3-4 were thyroid reduction (42%, 31% and 24%) and neutral granulocyte reduction (23%, 16% and 8%).
three groups also had 42 (54%), 40 (48%) and 35 (44%) severe adverse reactions, respectively;
14 deaths during the study period (5, 3 and 6 in the three groups A, B and C, respectively), and no deaths were determined to be related to treatment.
Pabissat 20mg 3 times/week with subsurfed injection boron tazomethami combined application is safer than in the past the dose and intravenous giving boron tezometri is better, suggesting that subdermi subsoil drug can also improve the tolerance of Papiss and his joint program.
the highest overall mitigation rate at 20mg/week and 20mg/week, and the best tolerance at 10mg/week.
。